EMA Application withdrawn: Cerepro (adenovirus-mediated Herpes simplex virus-thymidine kinase gene) — Ark Therapeutics

View source ↗

Summary

EMA withdrew the Cerepro gene therapy application for glioma from Ark Therapeutics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioma

Drugs mentioned

• Cerepro (sitimagene ceradenovec)

Snippet

Status: Application withdrawn. Therapeutic area: Glioma. MAH: Ark Therapeutics. Decision date: 31/12/2009. Orphan medicine